INDIVIDUAL/FOUNDATION FUNDING

Gates Foundation Grants $83.5M to Fight Malaria
The Bill & Melinda Gates Foundation committed $83.5 million in new grants to combat malaria by expanding access to bednets, treatment, and other malaria control tools; speed research on vaccines and other new prevention methods; and boost global advocacy to fight the disease.
Full Article

Koch Gives $20 Million for Hopkins Cancer Research
David Koch, a philanthropist and executive vice president of the nation’s largest privately owned company, Koch Industries Inc., has committed $20 million to support a new cancer research building on Johns Hopkins University’s East Baltimore, Md., medical campus.
Full Article

PRIVATE FUNDING

Kalypsys Raises $100M in Series C Financing
Kalypsys Inc., San Diego, has raised $100 million in a Series C financing that it will use to fund its broad range of preclinical and clinical programs in the areas of cardiovascular/metabolic diseases, pain/inflammation and oncology.
Full Article

Galil Medical Gains $52M
Galil Medical, Yokneam, Israel, a market leader in cryotherapy systems to treat cancer and non-cancerous tumors, announced the completion of a $52 million financing to expand its activities and invest in R&D and clinical programs to support cryotherapy technology.
Full Article

Cathay Completes $52M Series B Financing
Cathay Industrial Biotech Ltd., Shanghai, China, announced the closing of its $52 million Series B financing, which will be used to improve Cathay's long chain dibasic acids production technology by replacing the starting raw material from traditional alkanes to renewable bio-materials.
Full Article

Magellan Closes $50M Financing
Magellan Biosciences, Chelmsford, Mass., an emerging leader in clinical-diagnostic markets worldwide, closed a new $50 million round of debt and equity financing, to expand its growth through new product development and strategic acquisitions.
Full Article

Concert Pharmaceuticals Raises $48.5M in Series B Financing
Concert Pharmaceuticals Inc., Lexington, Mass., a pharmaceutical company developing novel small molecule drugs for unmet medical needs, has received $48.5 million in Series B financing to rapidly advance its diverse pipeline into clinical evaluation.
Full Article

Elixir Pharmaceuticals Raises $46M
Elixir Pharmaceuticals Inc., Cambridge, Mass., closed a Series C and venture debt financings, raising $46 million, including $31 million in equity funding, that will permit the company to develop therapeutics to treat major metabolic disorders, as well as to treat and prevent a broader range of age-related diseases.
Full Article

Orexigen Completes $30M Series C Financing
Orexigen Therapeutics Inc., San Diego, Calif., a privately held clinical-stage neuroscience company, completed a $30 million Series C private equity financing, which will be used to advance its clinical programs for two lead drug candidates to treat obesity.
Full Article

GRANTS AVAILABLE

Symptom Clusters in Cancer and Immune Disorders
Agency: National Institutes of Health
Estimated Funding: N/A
Due Date for Applications: Multiple dates, see Web site
Description: The goal of this funding opportunity announcement is to build a body of science in symptom cluster identification and intervention in cancer and in immune disorders (acquired or autoimmune).
Full Article

Proteomics: Diabetes, Obesity, And Endocrine, Digestive, Kidney, Urologic, And Hematologic Diseases
Agency: National Institutes of Health
Estimated Funding: N/A
Due Date for Applications: Multiple dates, see Web site
Description: This grant solicits projects that advance research to identify and quantitate protein expression patterns, post-translational modification of proteins, and protein-protein interactions on cells, tissues, organ systems relevant to diabetes, obesity, endocrine and metabolic diseases, nutritional function and diseases of the alimentary tract, exocrine pancreas, liver, kidney, bladder and prostate and normal biological processes related to the function of these systems.
Full Article

Development, Application, and Evaluation of Prediction Models for Cancer Risk and Prognosis
Agency: National Cancer Institute
Estimated Funding: N/A
Due Date for Applications: Multiple dates, see Web site
Description: The National Cancer Institute seeks applications for research projects to develop, apply, and evaluate new and existing cancer risk and prognostic prediction models for use by researchers, clinicians, and the general public.
Full Article

Developmental Biology and Regeneration of the Liver
Agency: National Institutes of Health
Estimated Funding: N/A
Due Date for Applications: Multiple dates, see Web site
Description: This grant invites qualified scientific investigators to submit applications on liver development and regeneration to fully define the molecular and cellular mechanisms underlying these processes in health and disease and to apply these findings to developing improved therapies for liver disease.
Full Article

Development of Disease Biomarkers
Agency: National Institutes of Health
Estimated Funding: N/A
Due Date for Applications: Multiple dates, see Web site
Description: This grant will provide resources to validate candidate biomarkers for well-defined human diseases of liver, kidney, urological tract, digestive and hematologic systems, and endocrine and metabolic disorders, diabetes and its complications, and obesity.
Full Article

Drug Discovery for Nervous System Disorders
Agency: National Institutes of Health
Estimated Funding: N/A
Due Date for Applications: Multiple dates, see Web site
Description: This grant invites qualified researchers to submit research grant applications directed toward the discovery, development, and preclinical testing of novel compounds for the prevention and treatment of nervous system disorders.
Full Article

Pancreatic Development and Regeneration: Toward Cellular Therapies for Diabetes
Agency: National Institutes of Health
Estimated Funding: N/A
Due Date for Applications: Multiple dates, see Web site
Description: This grant seeks applications to understand how endogenous pancreatic beta cells are made by studying pancreatic development, with the goal of making pancreatic islets in culture, to explore the potential of animal or human stem/progenitor cells as a source for making pancreatic islets, and to determine the basic mechanisms underlying beta cell regeneration in the adult as a basis for producing new cellular therapies for diabetes.
Full Article

Alzheimer s Disease Pilot Clinical Trials
Agency: National Institute on Aging
Estimated Funding: N/A
Due Date for Applications: Multiple dates, see Web site
Description: This grant invites qualified investigators to submit research grant applications for pilot clinical drug trials directed toward the prevention and treatment of the cognitive and behavioral symptoms of mild cognitive impairment, Alzheimer's disease, and age-related cognitive decline.
Full Article

Integrating Lung Genetics and Genomics in Human Populations
Agency: National Institutes of Health
Estimated Funding: N/A
Due Date for Applications: Multiple dates, see Web site
Description: This grant seeks to stimulate innovative approaches to merge genetic and genomic techniques to find genes associated with human complex traits for lung disease.
Full Article

Evolution of Infectious Diseases
Agency: National Institutes of Health
Estimated Funding: N/A
Due Date for Applications: Multiple dates, see Web site
Description: This grant solicits applications from institutions/organizations to study the evolutionary principles that underlie the emergence, spread, and containment of infectious disease.
Full Article

Research on the Cognitive Sequelae of Parkinson's Disease
Agency: National Institutes of Health
Estimated Funding: N/A
Due Date for Applications: Multiple dates, see Web site
Description: This grant invites applications that address the underlying neurobiological mechanisms associated with the cognitive impairment in Parkinson's disease, the development of clinical interventions and therapeutics for cognitive impairment, or that promote improved clinical diagnosis or treatment of cognitive impairment in Parkinson's.
Full Article

Clinical Studies of Bisphonate Therapy and Osteonecrosis of the Jaws
Agency: National Institutes of Health
Estimated Funding: N/A
Due Date for Applications: Multiple dates, see Web site
Description: This grant solicits applications to explore the association between osteonecrosis of the jaws and bisphosphonate therapy.
Full Article